CLL BTKi Therapy: FAQ Part 1
Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 1

Released: September 17, 2020

Expiration: September 16, 2021

Danielle M. Brander
Danielle M. Brander, MD
Jeffrey P. DONOTUSESharman
Jeffrey P. DONOTUSESharman, MD
Jeff DONOTUSESharman
Jeff DONOTUSESharman, MD
Nicole Lamanna
Nicole Lamanna, MD

Activity

Progress
1
Course Completed

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer questions focused on the optimizing BTK inhibitor therapy for previously untreated patients with CLL considering presentation characteristics and drug pharmacology.

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program, including associated downloadable slidesets: https://www.clinicaloptions.com/oncology/programs/cll-horizons